The epidemiology of factor VIII inhibitors

Haemophilia

Volumn 12, Issue SUPPL. 6, 2006, Pages 23-29

  Hay, Charles R M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Epidemiology; Factor VIII; Heredity; Inhibitors; Risk factors

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; HLA DR ANTIGEN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

AGE; ANTIBODY PRODUCTION; ARTICLE; BREAST FEEDING; COMORBIDITY; DRUG EXPOSURE; ENVIRONMENTAL EXPOSURE; ETHNOLOGY; FAMILY HISTORY; GENE DELETION; GENE REARRANGEMENT; GENOTYPE; HAPLOTYPE; HEMOPHILIA; HLA SYSTEM; HUMAN; INFECTION; INTRON; MISSENSE MUTATION; MOLECULAR EPIDEMIOLOGY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VACCINATION;

BLOOD COAGULATION FACTOR INHIBITORS; BREAST FEEDING; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMOPHILIA A; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 33751017726     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01362.x     Document Type: Article

References (39)

1. Colvin BT, Hay CRM, Hill FGH, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom 1990-1993. Br J Haematol 1995; 89: 908-10.
2. Addiego J, Kasper C, Abildgaard C et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
3. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
4. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
5. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
6. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
7. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII: C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. Blood 1988; 71: 344-8.
8. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 1992; 67: 600-2.
9. Frommel D, Allain JP. Genetic predisposition to develop factor VIII antibody in classic haemophilia. Clin Immunol Immunopathol 1977; 8: 34-8.
10. Shapiro SS. Genetic predisposition to inhibitor formation. Prog Clin Biol Res 1984; 150: 45-55.
11. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
12. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 2: 500-4.
13. Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E, the MIBS study group. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-30.
14. Berntorp E, Astermark J, Doonfield SM et al. Haemophilia Inhibitor Genetics Study -evaluation of a model for studies of complex diseases using linkage and associated methods. Haemophilia 2005; 11: 427-9.
15. Gill FM. The natural history of factor VIII inhibitors in patients with haemophilia A. In: Hoyer LW, ed. Factor VIII Inhibitors. New York: Alan R. Liss, 1984: 19-28.
16. Addiego JE, Kasper C, Abildgaard T et al. Increased frequency of inhibitors in African American hemophilic patients. Blood 1994; 1: 293a.
17. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients -a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
18. Goudemand J, Rothschild C, Demeiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 2006; 107: 46-51.
19. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
20. Hay CRM, Ollier W, Pepper L et al. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77: 234-7.
21. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
22. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert A-K, the MIBS Study Group. Polymorphisms in the IL10 but not the IL-1 β and IL-4 genes are associated with inhibitor development in patients with haemophilia A. Blood 2006; 107: 3167-72.
23. Yee TT, Lee CA. Oral immune tolerance induction to factor VIII via breast milk, a possibility ? Haemophilia 2000; 6: 591.
24. Knobe KE, Tengborn LI, Petrini P, Ljung RCR. Breastfeeding does not influence the development of inhibitors in haemophilia. Haemophilia 2002; 8: 657-9.
25. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
26. Van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. First treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-9.
27. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild haemophilia A. J Thromb Haemost 2003; 1: 1228-36.
28. Von Auer C, Oldenburg J, Von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of factor VIII concentrates. Ann NY Acad Sci 2005; 1051: 498-505.
29. DiMichele D, Kroner B. Higher immune tolerance (IT) success rate with monoclonal FVIII (mFVIII) when compared to recombinant (rFVIII): An analysis of The North American Immune Tolerance Registry (NAITR). Blood 2000; 96: 266a.
30. Kreuz W, Ettinghausen CE, Zyschka A et al. Inhibitor development in previously untreated patients with hemophilia A: A prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002; 28: 285-90.
31. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-83.
32. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
33. Schwarzinger I, Pabinger I, Korninger C et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Haematol 1987; 24: 241-5.
34. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-71.
35. Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophylised cryoprecipitate. Blood 1993; 81: 3332-5.
36. Guerois C, Laurian Y, Rothschild C et al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-8.
37. Schimpf K, Schwarz P, Hunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73: 997.
38. Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997; 78: 1027.
39. Kreuz W, Gill JC, Rothschild C et al. Full length sucrose formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: Results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.